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Abstract
As the process of tumor progression proceeds from the
normal cellular state to a preneoplastic condition and
finally to the fully invasive form, the molecular charac-
teristics of the cell change as well. These character-
istics can be considered a molecular fingerprint of the
cell at each stage of progression and, analogous to
fingerprinting a criminal, can be used as markers of the
progression process. Based on this premise, the Can-
cer Genome Anatomy Project was initiated with the
broad goal of determining the comprehensive molecu-
lar characterization of normal, premalignant, and malig-
nant tumor cells, thus making a reality the identification
of all major cellular mechanisms leading to tumor initia-
([tion and progression Strausberg, R.L., Dahl, C.A., and
( )Klausner, R.D. 1997 . ‘‘New opportunities for uncover-
ing the molecular basis of cancer.’’ Nat. Genet., 16:
] )415–516. , www.ncbi.nlm.nih.gov/ncicgap/ . The expec-
tation of determining the genetic fingerprints of cancer
)progression will allow for 1 correlation of disease pro-
)gression with therapeutic outcome; 2 improved evalua-
)tion of disease treatment; 3 stimulation of novel ap-
)proaches to prevention, detection, and therapy; and 4
enhanced diagnostic tools for clinical applications.
Whereas acquiring the comprehensive molecular analy-
sis of cancer progression may take years, results from
initial, short-term goals are currently being realized and
are proving very fruitful.
Initial Goals of the Cancer Genome Anatomy Project
The first of the initial CGAP goals is to establish a Tumor
( )Gene Index TGI to serve as a catalogue of all genes
expressed in the cancer progression process, with special
(reference to tumor type and stage of progression http://
[ ])www.ncbi.nlm.nih.gov/ncicgap/EST/cgaplb.cgi; 1 . Estab-
lishment of the TGI is being done by constructing cDNA
libraries from pathological tissue followed by high-through-
put library sequencing. In general, this approach was used
successfully to develop the Expressed Sequence Tag
( )database dbEST by the National Center for Biotechnology
( ) ([ ]Information NCBI and the I.M.A.G.E. consortium 2,3 ;
)http://www.ncbi.nlm.nih.gov/dbEST/ index.html . The TGI
uses the existing infrastructure of dbEST and amounts to a
catalogue of all the genes that are expressed across the
entire spectrum of cancer progression, with special attention
to prostate, breast, ovarian, lung, and colon cancers. A
secondary goal in developing the TGI was to identify
the remaining members of the unique human gene set,
([ ]represented by UniGene set of genes 4,5 ; http://
)www.ncbi.nlm.nih.gov/UniGene/ index.html . In addition, as
EST mapping proceeds and every UniGene cluster is even-
tually placed on the human transcript map, region-specific
catalogues of genes will exist that can be matched to
genomic ‘‘hotspots’’ correlating with specific cancer types
([ ]and stages 6–10 ; http://www.ncbi.nlm.nih.gov/genemap/ ,
)http://www.ncbi.nlm.nih. gov/CCAP/NG/ .
To develop the TGI and build on existing databases in
parallel, two types of CGAP-specific cDNA libraries are
currently in use. Standard bulk tissue cDNA libraries from
RNA derived from large tumor tissues function primarily to
create a general picture of those genes expressed in the
tumor process in addition to driving the process of gene
discovery to aid the UniGene effort. More than 80 bulk
(tissue cDNA libraries normalized as well as non-normal-
)ized from a wide range of tumor types and histologies have
been sequenced, and to date more than 340,000 ESTs
have been deposited in the TGI. In addition, more than
11,000 novel genes have been discovered thus far to sup-
plement the UniGene set. Although these results have
proven extremely useful, a serious drawback to the se-
quencing of bulk tissue cDNA libraries is the lack of gene
expression information in the context of tumor biology. This
is primarily due to cellular heterogeneity found in bulk tis-
sue.
Histological examination reveals that the prostate is a
complex organ comprising of multiple cell types. Only 10%
of the cells are epithelial in origin, whereas the remaining
90% of the organ comprises of inflammatory, fibroblastic,
endothelial, and nervous cells. Yet it is the epithelium that
[ ]gives rise to life-threatening prostate cancer 11,12 . Armed
with this information, it is quite easy to understand why any
attempts to determine a prostate epithelial–specific gene
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profile would fail by sequencing a bulk tissue cDNA library
from a normal prostate gland. Furthermore, bulk tumor
tissue will undoubtedly contain inflammatory, structural, and
endothelial cells regardless of the percent of tumor cells in
the tissue as determined histologically. It was this realiza-
tion that led to the development of laser capture microdis-
( ) [ ]section LCM 13,14 .
LCM is a process by which one is able to procure
selected groups of cells, or even individual cells, from a
heterogeneous population of cells in standard pathology
preparations. The second type of cDNA library used in
[ ]CGAP is constructed from RNA obtained by LCM 15,16 .
These libraries make it possible for the first time, to perform
large-scale, in vivo gene expression profiling from a specific
cell type. To begin addressing the issue of gene expression
and profiling in the process of prostate cancer progression,
a total of 15 cDNA libraries have been constructed from
( )normal epithelium, prostatic intraepithelial neoplasia PIN
lesions, invasive tumor cells, and metastatic prostate le-
sions. Many of these libraries were constructed from cells
dissected from the same patient and pathology preparation.
More than 30,000 clones have been sequenced from these
libraries, representing 5186 UniGene clusters. Not only are
these sequences useful for prostate tissue–specific and
prostate cancer stage–specific expression analysis, they
are useful for gene discovery, as evidenced by the estab-
lishment of greater than 400 UniGene clusters. Thus these
libraries possess the potential to discover weakly ex-
pressed, tissue-specific, and cell-specific transcripts not
easily found in bulk tissue libraries.
CGAP bioinformatics
With the recent surge in genetic information available to the
cancer researcher, it is apparent that useful bioinformatics
packages need to be developed to address these issues.
The CGAP Website has been actively pursuing this en-
deavor in trying to deliver tools that would allow the individ-
ual investigator to tease out interesting gene expression
data from all of the cDNA libraries that currently exist in the
( )TGI. One such function is Digital Differential Display DDD .
[ ]This utility uses the Fisher exact test 17 to compare one
library to another, a pool of libraries to a single library, or a
pool of libraries against another pool. In addition, all cDNA
libraries that exist in dbEST can be used, not just those
from CGAP. This allows for flexibility in designing an experi-
ment in silica and many questions can be asked using this
function.
For example, one may obtain a list of tissue-specific
genes for the prostate by constructing several pools for the
(DDD to analyze http://www.ncbi.nlm.nih. gov /ncicgap/
)ddd.html . This working example is entitled ‘‘Compare
Stages of Prostate Cancer’’ and can be viewed on the URL
listed above. Detailed instructions for using DDD can also
be found at this site. To find tissue-specific genes, a control
pool should consist of libraries specific to several tissues
different from each other and from the tissue of interest, and
the pools of interest should contain libraries which are as
narrowly focussed as possible. In addition, a control pool
should consist of several diverse libraries with many se-
quences. Choosing libraries too similar to each other for the
(control pool for instance, several different libraries con-
Figure 1. DDD page showing the choice of pools used for this analysis.
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)structed from brain tissue would simply identify genes not
expressed in brain tissue and not a superset of genes
specific to prostate tissue. A similar difficulty would arise
were the control pool to contain libraries with few ESTs.
One would obtain genes not expressed in the small control
pool, of which the tissue-specific genes would be a small
fraction. Thus, we choose the libraries ‘‘Normalized infant
( )brain 1NIB’’ 45472 ESTs and ‘‘Soares fetal liver spleen
( ) ( )1NFLS S1’’ 29545 ESTs for our control pool Figure 1 .
Because the pools are easily edited, one may test to ensure
that the results are independent of the choice of control pool
by modifying the control pool at a later stage in the analysis.
Next, one chooses libraries for three prostate-specific
pools; this is preferable to grouping the diverse libraries in
a single pool because differences between the pools indi-
cate the extent to which any gene is specific to normal,
neoplastic, or preneoplastic tissue. We choose library
‘‘NCI CGAP Pr1, Microdissected, normal prostate epithe-
Figure 2. Result page from the DDD analysis indicating 7 statistically significant prostate-specific transcripts. Many more transcripts were found, and
those can be found on the DDD website as described in the text.
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lium’’ to exemplify normal tissue, ‘‘NCI CGAP Pr2, Mi-
crodissected, low grade prostatic intraepithelial neoplasia’’
to exemplify preneoplastic tissue, and ‘‘NCI CGAP Pr3,
Microdissected, invasive prostate tumor’’ to exemplify neo-
plasia.
Because one of the pools is a diverse control, all
prostate-specific genes expressed in one of the tissue-
specific pools are listed; furthermore, differences between
the pools are also listed. Note that comparing only
prostate-specific normal and cancerous libraries would pro-
duce very few significant differences. Although the use of
these as separate pools compared with a control pool
displays differences that are not statistically significant, these
genes would nonetheless amount to candidate genes in-
volved in prostate cancer progression and may prove very
useful to the cancer biologist as potential leads to experi-
mental follow-up. Statistical significance is at the P-s .05
[ ]level for the Fisher exact test 17 . To see whether
the differences found are due to idiosyncrasies of the
libraries chosen, we can expand the pools by adding the
(Figure 3. Display of a gene expression profile analysis from the following microdissected cDNA libraries: Lib.281 NCI_CGAP_Pr1, microdissected
) ( ) ( )normal epithelium , Lib.282 NCI_CGAP_Pr2, microdissected preneoplastic lesion , and Lib.283 NCI_CGAP_Pr3, microdissected invasive tumor .
Neoplasia v Vol. 1, No. 2, June 1999
CGAP and Cancer Progression Krizman et al. 105
following: for normal libraries, ‘‘NCI CGAP Pr9 Microdis-
sected, normal prostate epithelium,’’ and ‘‘NCI CGAP
Pr25, Cell line, normal prostate epithelial cell line’’; for
precancerous libraries, ‘‘NCI CGAP Pr4, Microdissected,
high grade prostatic intraepithelial neoplasia’’ and
‘‘NCI CGAP Pr4.1, Microdissected, high grade prostatic
intraepithelial neoplasia high grade’’; and for cancerous
libraries, ‘‘NCI-CGAP Pr24, Cell line, invasive prostate tu-
( )mor cell line HPV immortalized ,’’ ‘‘NCI CGAP Pr10,
Microdissected, invasive prostate tumor,’’ and ‘‘NCI
CGAP Pr8, Microdissected, invasive prostate tumor.’’
There are two genes with significant differences between
states in the small and large pools: prostate specific antigen
( ) ( )PSA and beta-microseminoprotein prostate secreted
( ) ( )MSMB Figure 2 . Although not statistically significant ac-
cording to the Fisher test, we note that kallikrein also has
different expression levels in normal and precancerous tis-
sues, as do several ribosomal proteins. MSMB and kallikrein
[ ]have been implicated in prostate cancer 18–21 . This sug-
gests that UniGene clusters with similar expression profiles
would be potential candidates for the molecular fingerprint-
ing of the stages of prostate cancer. Note that UniGene
cluster identifiers, although superficially very convenient as
referents, are not guaranteed to be stable for archival pur-
poses. This is because clusters may split or merge together
with the addition of new sequences. Thus, it is safest to
store the list of accession numbers in a cluster of interest.
The Fisher exact test, which is used to assess whether
the difference in expression levels, is known to be conserva-
tive. It is therefore useful to have an independent tool to
examine differences in expression level. The gene expres-
(sion comparison utility http://www.ncbi.nlm.nih.gov/ncicgap
) ( )/EST/cgapqr.cgi Figure 3 does not attempt to assess
statistical significance but can be used to identify which
libraries have contributed sequences to a gene of interest.
One difficulty particularly relevant in seeking novel ESTs is
the observation that the Fisher exact test will not find a
significant difference in expression levels for small clusters.
The exact definition of small clusters depends on the total
number of sequences in the pools being compared but, for
instance, clusters of size 1 are never statistically significant.
Thus, the Fisher exact test and the DDD interface to the test
will tend to identify larger clusters and thus already charac-
terized genes.
Two recent studies have demonstrated the usefulness of
[ ]these prostate cDNA libraries 22,23 . A combination of
computer-based analysis and laboratory analysis identified
a number of genes from the prostate libraries within the TGI
that have shown patterns of prostate-specific expression.
The investigators suggest the procedure they used can be
easily applied to the discovery of genes expressed in others
organs or tumors.
Conclusions and Future CGAP Goals
The DDD and gene expression comparison utilities are tools
that currently exist to analyze CGAP-generated data. The
CGAP website has historically been dynamic and is in
continuous flux according to the data present in the TGI;
thus all utilities are subject to continual improvements and
upgrades. The example outlined in this article focused on
prostate cancer. The immediate CGAP goal is to complete
construction and sequencing of analogous cDNA libraries
from microdissected cells representing all stages of ovarian,
lung, colon, and breast cancers. Thus, analysis of the gene
expression profiles of these first 5 cancers will undoubtedly
render unprecedented bioinformation to the cancer commu-
nity. More tumors will likely be added to this list once these
5 are completed.
A future goal for the analysis of gene expression in
cancer progression is the development and use of serial
( )analysis of gene expression SAGE cDNA libraries from
[ ]cancer tissue 24 . A number of these libraries have recently
been constructed and sequenced by CGAP, and utilities to
(analyze these data are starting to emerge http://
)www.ncbi.nlm.nih.gov/SAGE/ . Due to the larger amount of
data that can be obtained by sequencing SAGE libraries,
greater statistical significance to computer-generated gene
expression analysis can be ascribed to these analyses.
However, because these libraries were generated from bulk
tumor tissue and not microdissected cells, direct compari-
son of tumor to preneoplastic or normal cellular states
cannot be made. Thus, an ideal gene expression analysis of
cancer progression might be the application of SAGE tech-
nology to microdissected cells.
In addition to expanding and improving the usefulness of
gene expression profiles generated from sequencing cDNA
libraries, CGAP has recently committed to the study of
cancer progression at the genomic level by establishment of
( )the Genetic Annotation Initiative GAI and the Cancer Chro-
( )mosome Aberration Project cCAP . The GAI goal is to
discover and catalogue single nucleotide polymorphisms in
( )cDNA sequence SNPs that correlate with cancer initiation
and progression, whereas the goal of cCAP is to develop a
set of tools that will allow for the expedient definition and
detailed characterization of chromosomal alterations associ-
ated with cancer initiation and progression.
Expansion to model organisms is beginning to take shape
within CGAP as well. Establishment of the mouse TGI will
take place in the near future that will mirror the current
human TGI in that both bulk tumor tissue and microdis-
sected cells will be used to generate cDNA libraries for
high-throughput sequencing. Like the human TGI, the 5
cancers of focus for the mouse are prostate, breast, lung,
colon, and ovarian cancers.
In conclusion, the CGAP encompasses an entire ap-
proach to understanding cancer at the molecular level. Even
in its infancy it shows great promise for uncovering impor-
tant gene expression changes involved in cancer initiation
and progression. An example for discovering such changes
has been outlined here. In the near future one could envi-
sion that as the TGI grows linearly, possibilities for bioinfor-
matics could expand exponentially. With addition of the new
CGAP initiatives discussed here, the National Cancer Insti-
tute optimistically looks forward to uncovering the molecular
changes that lead to cancer initiation and progression.
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